NCT06186167 is a clinical trial of Chest Wall Fat Tissue Collection in Amyloid, sponsored by Midwest Heart & Vascular Specialists.

Who is sponsoring NCT06186167?

NCT06186167 is sponsored by Midwest Heart & Vascular Specialists.

What drugs are being tested in NCT06186167?

Interventions in NCT06186167: Chest Wall Fat Tissue Collection.

What condition does NCT06186167 study?

NCT06186167 studies Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis, AL Amyloidosis, Infiltrative Cardiomyopathy, Amyloid, ATTR Amyloidosis Wild Type.

Is NCT06186167 still recruiting?

NCT06186167 is currently status unknown. Last updated 20 February 2024.

Last reviewed 2024-02-20 · How we verify

NCT06186167

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amyloidosis Incidence in High-Risk Cardiac Device Patients

Status unknown Last updated 20 February 2024

What this trial tests

trial testing Chest Wall Fat Tissue Collection in Amyloid in 100 participants. Status unknown.

Timeline

29 January 2024

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Midwest Heart & Vascular Specialists
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	29 January 2024
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across United States

Drugs / interventions tested

Chest Wall Fat Tissue Collection

Conditions studied

Amyloid — all drugs for Amyloid →
Cardiac Amyloidosis — all drugs for Cardiac Amyloidosis →
Amyloidosis Cardiac — all drugs for Amyloidosis Cardiac →
Systemic Amyloidosis — all drugs for Systemic Amyloidosis →

Sponsor

Midwest Heart & Vascular Specialists

Who can join

40 and older, any sex, with Amyloid or Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a new, non-invasive diagnostic avenue for this condition.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Amyloid

Currently open trials in the same condition.

NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
NCT07130565 — Pan-Amyloid PET/CT in Various Amyloid-Related Disease · recruiting
NCT05138848 — Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease · EARLY_PHASE1 · recruiting
NCT06725706 — Beta Amyloid PET/CT in Various Aβ-Related Disease · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06186167 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Midwest Heart & Vascular Specialists
Last refreshed: 20 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06186167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing